

## FOI 24/155 EXXUA (Gepirone) availability.

MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>

Thu 07/03/2024 19:17

To [REDACTED]

Dear [REDACTED]

We think we may have received the same enquiry twice from you; you asked on 14 February about the availability of "EXXUA (Gepirone)" and if there are plans to approve this medication for UK use (your email below).

You had also asked this on 6 February 2024, and we responded to this request as FOI 24/138 on 5 March 2024. We've copied that response below for you; it's below your more recent email. Our apologies for writing again, but we wanted to make sure we had responded to both of your enquiries.

Yours sincerely,

**MHRA Customer Experience Centre**  
Communications and engagement team  
Medicines and Healthcare products Regulatory Agency  
10 South Colonnade, Canary Wharf, London E14 4PU

---

**From:** [REDACTED]

**Sent:** Wednesday, February 14, 2024 2:13 PM

**To:** MHRA Customer Services <[MHRACustomerServices@mhra.gov.uk](mailto:MHRACustomerServices@mhra.gov.uk)>

**Subject:** FOI 24/155 EXXUA (Gepirone) availability.

Hi.

I have highly treatment resistant (and depressive in nature) bipolar NOS and have pretty much run out of options.

I note that EXXUA (Gepirone) has recently received FDA approval for the treatment depression - and in the past I have best responded to serotonergics. NICE have advised me to contact you regarding UK availability. Can you tell me if there are plans to approve this medication for UK use? Would it be available at least privately in the near future?

Many thanks,

[REDACTED]

Sent from [Outlook for Android](#)

---

**From:** MHRA Customer Services

**Sent:** Tuesday, March 5, 2024 3:04 PM

**To:** [REDACTED]

**Subject:** FOI 24/138 Gepirone availability

**FOI 24/138**

Dear [REDACTED]